G

Guobang Pharma Ltd
SSE:605507

Watchlist Manager
Guobang Pharma Ltd
SSE:605507
Watchlist
Price: 21.27 CNY -3.23% Market Closed
Market Cap: 11.8B CNY
Have any thoughts about
Guobang Pharma Ltd?
Write Note

Guobang Pharma Ltd
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Guobang Pharma Ltd
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
G
Guobang Pharma Ltd
SSE:605507
Research & Development
-ÂĄ170m
CAGR 3-Years
-9%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Research & Development
-ÂĄ2.1B
CAGR 3-Years
-19%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Research & Development
-ÂĄ232.3m
CAGR 3-Years
-31%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Research & Development
-ÂĄ5.8B
CAGR 3-Years
0%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Research & Development
-ÂĄ339.2m
CAGR 3-Years
-19%
CAGR 5-Years
-22%
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Research & Development
-ÂĄ712.5m
CAGR 3-Years
-61%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Guobang Pharma Ltd
Glance View

Market Cap
11.8B CNY
Industry
Pharmaceuticals

Guobang Pharma Ltd. engages in the research, development, manufacturing and sale of pharmaceutical products. The company is headquartered in Shaoxing, Zhejiang and currently employs 3,326 full-time employees. The company went IPO on 2021-08-02. The firm's pharmaceutical business includes raw materials, key pharmaceutical intermediates and preparations, and its main products include azithromycin, clarithromycin, and roxithromycin cephalosporin series products. The animal health products business includes animal protection raw materials, animal protection additives and preparations. The main products of veterinary antibiotics include florfenicol, enrofloxacin series, etc., and insecticides include diclazuril and cypronamine, and reparation products include premixes, powders, granules, etc.

Intrinsic Value
34.07 CNY
Undervaluation 38%
Intrinsic Value
Price
G

See Also

What is Guobang Pharma Ltd's Research & Development?
Research & Development
-170m CNY

Based on the financial report for Dec 31, 2023, Guobang Pharma Ltd's Research & Development amounts to -170m CNY.

What is Guobang Pharma Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
-12%

Over the last year, the Research & Development growth was 8%. The average annual Research & Development growth rates for Guobang Pharma Ltd have been -9% over the past three years , -12% over the past five years .

Back to Top